Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma

Cancer Biomarkers

Volumn 7, Issue 6, 2010, Pages 261-268

  Kroeze, S G C ^a   Bijenhof, A M ^a   Bosch, J L H R ^a   Jans, J J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

biomarker; clear cell renal cell carcinoma; Papillary renal cell carcinoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BETA DEFENSIN 1; BIOLOGICAL MARKER; CLAUDIN 1; CLAUDIN 7; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CXCL16 CHEMOKINE; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN 8; ENDOTHELIN 1; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HERMES ANTIGEN; HYPOCALCIN; KI 67 ANTIGEN; MERLIN; MUCIN 1; PARVALBUMIN; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C RECEPTOR; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VITAMIN D RECEPTOR; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CLEAR CELL RENAL CELL CARCINOMA; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MASS SPECTROMETRY; NEPHRECTOMY; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; TUMOR GROWTH;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959740057     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2010-0195     Document Type: Review

References (42)

1. J.M. Hollingsworth, D.C. Miller, S. Daignault and B.K. Hollenbeck, Rising incidence of small renal masses: a need to reassess treatment effect, J Natl Cancer Inst 98 (2006), 1331-1334. (Pubitemid 44530728)
2. A.J.Cambio and C.P. Evans, Management approaches to small renal tumours, BJU Int 97 (2006), 456-460.
3. C.J. Robson, B.M. Churchill and W. Anderson, The results of radical nephrectomy for renal cell carcinoma. 1969, J Urol 167 (2002), 873-875; discussion 876-877.
4. B. Ljungberg, F.I. Alamdari, T. Rasmuson and G. Roos, Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy, BJU Int 84 (1999), 405-411. (Pubitemid 29419406)
5. R.J. Motzer, N.H. Bander and D.M. Nanus, Renal-cell carcinoma. N Engl J Med 335 (1996), 865-875.
6. A. Zisman, A.J. Pantuck, J. Wieder, D.H. Chao, F. Dorey et al., Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma, J Clin Oncol 20 (2002), 4559-4566. (Pubitemid 35402959)
7. A. Lopez-Beltran, J.C. Carrasco, L. Cheng, M. Scarpelli Z. Kirkali et al., 2009 update on the classification of renal epithelial tumors in adults, Int J Urol 16 (2009), 432-443.
8. B. Delahunt, J.N. Eble, M.R. McCredie, P.B. Bethwaite, J.H. Stewart et al., Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases, Hum Pathol 32 (2001), 590-595. (Pubitemid 32601240)
9. Y. Allory, D. Ouazana, E. Boucher, N. Thiounn and A. Vieillefond, Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases, Virchows Arch 442 (2003), 336-342. (Pubitemid 36561090)
10. A.N.Young,V.A. Master andM.B.Amin, Current trends in the molecular classification of renal neoplasms, ScientificWorld- Journal 6 (2006), 2505-2518.
11. U. Capitanio, V. Cloutier, L. Zini, H. Isbarn, C. Jeldres et al., A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study, BJU Int 103 (2009), 1496-1500.
12. T.K. Choueiri, A. Plantade, P. Elson, S. Negrier, A. Ravaud et al., Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma, J Clin Oncol 26 (2008), 127-131.
13. M.B. Atkins, Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy, Med Oncol 26(1) (2009), 18-22.
14. G.Hudes,M. Carducci, P. Tomczak, J.Dutcher, R. Figlin et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med 356 (2007), 2271-2281. (Pubitemid 46849157)
15. R.J.Motzer, T.E.Hutson, P. Tomczak,M.D.Michaelson, R.M. Bukowski et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med 356 (2007), 115-124. (Pubitemid 46089672)
16. H.S. Tunuguntla and M. Jorda, Diagnostic and prognostic molecular markers in renal cell carcinoma, J Urol 179 (2008), 2096-2102.
17. C. Eichelberg, K. Junker, B. Ljungberg and H. Moch, Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability, Eur Urol 55 (2009), 851-863.
18. M.S. Tretiakova, S. Sahoo, M. Takahashi, M. Turkyilmaz, N.J. Vogelzang et al., Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma, Am J Surg Pathol 28 (2004), 69-76. (Pubitemid 38031623)
19. Y.T. Chen, J.J. Tu, J. Kao, X.K. Zhou and M. Mazumdar, Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma, Clin Cancer Res 11 (2005), 6558-6566. (Pubitemid 41338995)
20. Y. Allory, C. Bazille, A. Vieillefond, V. Molinie, B. Cochand- Priollet et al., Profiling and classification tree applied to renal epithelial tumours, Histopathology 52 (2008), 158-166.
21. W. Huang, K. Kanehira, S. Drew and T. Pier, Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study, Appl Immunohistochem Mol Morphol 17 (2009), 12-17.
22. P.R. Mazal, M. Stichenwirth, A. Koller, S. Blach, A. Haitel et al., Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study, Mod Pathol 18 (2005), 535-540. (Pubitemid 40478117)
23. B.F. Skinnider, A.L. Folpe, R.A. Hennigar, S.D. Lim, C. Cohen et al., Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors, Am J Surg Pathol 29 (2005), 747-754. (Pubitemid 40734424)
24. C. Langner, B.J. Wegscheider, M. Ratschek, L. Schips and R. Zigeuner, Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: A systematic analysis of 233 tumors, Virchows Arch 444 (2004), 127-134. (Pubitemid 38315289)
25. R. Zigeuner, M. Ratschek, P. Rehak, L. Schips and C. Langner, Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue, Urology 63 (2004), 651-655. (Pubitemid 38479402)
26. A. Haferkamp, J. Bedke, C. Vetter, M. Pritsch, N. Wagener et al., High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma, BJU Int 102 (2008), 1700-1706.
27. C. Kempkensteffen, S. Hinz, F. Christoph, H. Krause, J. Koellermann et al., Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome, Tumour Biol 28 (2007), 132-138. (Pubitemid 46975999)
28. A.S. Parker, F. Kosari, C.M. Lohse, R. Houston Thompson, E.D. Kwon et al., High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma, Cancer 107 (2006), 37-45. (Pubitemid 43939028)
29. M.H. Bui, H. Visapaa, D. Seligson, H. Kim, K.R. Han et al., Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma, J Urol 171 (2004), 2461-2466. (Pubitemid 38625515)
30. T. Klatte, D.B. Seligson, J. LaRochelle, B. Shuch, J.W. Said et al., Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy, Cancer Epidemiol Biomarkers Prev 18 (2009), 894-900.
31. N. Rioux-Leclercq, J.I. Epstein, J.Y. Bansard, B. Turlin, J.J. Patard et al., Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma, Hum Pathol 32 (2001), 1209-1215. (Pubitemid 33104432)
32. A. Haitel, H.G. Wiener, B. Neudert, M. Marberger and M. Susani, Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance, Urology 58 (2001), 477-481. (Pubitemid 32816374)
33. T. Migita, Y. Oda, S. Naito and M. Tsuneyoshi, Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma, Cancer 94 (2002), 973-979. (Pubitemid 34150851)
34. R.H.Weiss, A.D. Borowsky, D. Seligson, P.Y. Lin, L. Dillard- Telm et al., p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches, J Urol 177 (2007), 63-68; discussion 68-69.
35. W.Y. Kim and W.G. Kaelin, Role of VHL gene mutation in human cancer, J Clin Oncol 22 (2004), 4991-5004. (Pubitemid 46646218)
36. C. Di Cristofano, A. Minervini, M. Menicagli, G. Salinitri, G. Bertacca et al., Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression, Am J Surg Pathol 31 (2007), 1875-1881. (Pubitemid 350175815)
37. E. Yildiz, G. Gokce, H. Kilicarslan, S. Ayan, O.F. Goze et al., Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma, BJU Int 93 (2004), 1087-1093. (Pubitemid 38758639)
38. B. Liao, Y. Hu, D.J. Herrick and G. Brewer, The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells, J Biol Chem 280 (2005), 18517-18524. (Pubitemid 41389102)
39. Z. Jiang, C.M. Lohse, P.G. Chu, C.L. Wu, B.A. Woda et al., Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas, Cancer 112 (2008), 2676-2682. (Pubitemid 351969211)
40. T. Klatte, A.J. Pantuck, J.W. Said, D.B. Seligson, N.P. Rao et al., Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma, Clin Cancer Res 15 (2009), 1162-1169.
41. A.S. Parker, B.C. Leibovich, C.M. Lohse, Y. Sheinin, S.M. Kuntz et al., Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma, Cancer 115 (2009), 2092-2103.
42. H.L. Kim, D. Seligson, X. Liu, N. Janzen, M.H. Bui et al., Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma, J Urol 173 (2005), 1496-1501. (Pubitemid 40524757)